Telmisartan
Authoritative Clinical Reference
Navigation
DRUG NAME: Telmisartan
Therapeutic Class: Antihypertensive
Subclass: Angiotensin II Receptor Blocker (ARB)
Speciality: Cardiology
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
• Tablets: 20 mg, 40 mg, 80 mg
ADULT INDICATIONS + DOSING
Primary Indications (Approved / Standard in India)
1. Hypertension
| Step | Dose | Notes |
| Starting dose | 20–40 mg once daily | Use 20 mg in volume-depleted patients, those on diuretics, or elderly; most patients can be started at 40 mg |
| Titration | Increase to 80 mg once daily after 4 weeks if blood pressure target not achieved | |
| Usual maintenance dose | 40–80 mg once daily | |
| Maximum dose | 80 mg once daily | No additional benefit demonstrated beyond 80 mg |
• Telmisartan has the longest half-life among ARBs (~24 hours), providing consistent 24-hour blood pressure control with true once-daily dosing. High trough-to-peak ratio ensures sustained overnight and early-morning blood pressure coverage — clinically relevant for reducing morning surge-related cardiovascular events.
• Can be taken with or without food; absorption is not significantly affected by meals.
• Can be used as monotherapy or in combination with other antihypertensives. Commonly combined with hydrochlorothiazide, chlorthalidone, or amlodipine — widely available as fixed-dose combinations (FDCs) in India.
• If blood pressure is not controlled on telmisartan 80 mg monotherapy, addition of a low-dose thiazide/thiazide-like diuretic or calcium channel blocker is preferred over exceeding the maximum dose.
• First-dose hypotension risk is lower than with ACE inhibitors but still relevant in volume-depleted or salt-depleted patients — correct volume status or reduce diuretic dose before starting.
• Listed on NLEM India 2022 (40 mg tablet) — preferred ARB for public health use in India.
• Can be taken with or without food; absorption is not significantly affected by meals.
• Can be used as monotherapy or in combination with other antihypertensives. Commonly combined with hydrochlorothiazide, chlorthalidone, or amlodipine — widely available as fixed-dose combinations (FDCs) in India.
• If blood pressure is not controlled on telmisartan 80 mg monotherapy, addition of a low-dose thiazide/thiazide-like diuretic or calcium channel blocker is preferred over exceeding the maximum dose.
• First-dose hypotension risk is lower than with ACE inhibitors but still relevant in volume-depleted or salt-depleted patients — correct volume status or reduce diuretic dose before starting.
• Listed on NLEM India 2022 (40 mg tablet) — preferred ARB for public health use in India.
2. Cardiovascular Risk Reduction (in patients at high vascular risk who are intolerant to ACE inhibitors)
| Step | Dose | Notes |
| Starting dose | 80 mg once daily | Full dose from initiation |
| Usual maintenance dose | 80 mg once daily | |
| Maximum dose | 80 mg once daily | |
| Duration | Long-term (indefinite) |
• Based on the ONTARGET trial (2008): telmisartan 80 mg was non-inferior to ramipril 10 mg for the composite of cardiovascular death, myocardial infarction, stroke, and hospitalisation for heart failure in patients with vascular disease or high-risk diabetes.
• Primary role is in patients intolerant to ACE inhibitors (typically due to persistent dry cough) who require RAAS blockade for cardiovascular protection.
• The TRANSCEND trial further supported telmisartan in ACE inhibitor-intolerant patients, showing reduction in composite cardiovascular endpoints (secondary analysis).
• Do not combine telmisartan with an ACE inhibitor for dual RAAS blockade — the ONTARGET combination arm showed increased renal adverse events without additional cardiovascular benefit.
• Applicable in patients aged ≥55 years with established atherosclerotic cardiovascular disease (coronary artery disease, peripheral arterial disease, cerebrovascular disease) or type 2 diabetes with end-organ damage.
• Primary role is in patients intolerant to ACE inhibitors (typically due to persistent dry cough) who require RAAS blockade for cardiovascular protection.
• The TRANSCEND trial further supported telmisartan in ACE inhibitor-intolerant patients, showing reduction in composite cardiovascular endpoints (secondary analysis).
• Do not combine telmisartan with an ACE inhibitor for dual RAAS blockade — the ONTARGET combination arm showed increased renal adverse events without additional cardiovascular benefit.
• Applicable in patients aged ≥55 years with established atherosclerotic cardiovascular disease (coronary artery disease, peripheral arterial disease, cerebrovascular disease) or type 2 diabetes with end-organ damage.
Secondary Indications — only Adults (Off-label, if any)
1. Diabetic Nephropathy / Proteinuric Chronic Kidney Disease — OFF-LABEL for telmisartan specifically; class effect of ARBs
• Dose: 40–80 mg once daily
• Duration: Long-term
• Specialist only: Co-management with nephrologist recommended when eGFR <30 mL/min/1.73 m²
• Evidence basis: DETAIL trial (telmisartan vs enalapril in type 2 diabetic nephropathy) demonstrated equivalent renoprotection. The antiproteinuric effect of ARBs is well established (RENAAL and IDNT trials were with losartan and irbesartan respectively, but class effect is accepted in Indian nephrology practice). Telmisartan is commonly used for this purpose in Indian clinical practice.
• Clinical notes: Monitor serum creatinine and potassium within 1–2 weeks of initiation. Accept up to 30% rise in creatinine from baseline. Higher doses (80 mg) provide greater antiproteinuric effect independent of blood pressure reduction.
• Duration: Long-term
• Specialist only: Co-management with nephrologist recommended when eGFR <30 mL/min/1.73 m²
• Evidence basis: DETAIL trial (telmisartan vs enalapril in type 2 diabetic nephropathy) demonstrated equivalent renoprotection. The antiproteinuric effect of ARBs is well established (RENAAL and IDNT trials were with losartan and irbesartan respectively, but class effect is accepted in Indian nephrology practice). Telmisartan is commonly used for this purpose in Indian clinical practice.
• Clinical notes: Monitor serum creatinine and potassium within 1–2 weeks of initiation. Accept up to 30% rise in creatinine from baseline. Higher doses (80 mg) provide greater antiproteinuric effect independent of blood pressure reduction.
2. Heart Failure with Reduced Ejection Fraction (HFrEF) — OFF-LABEL; Specialist only
• Dose: 40–80 mg once daily
• Duration: Long-term
• Specialist only: Use only when ACE inhibitors and preferred ARBs (valsartan, candesartan) are not available or tolerated
• Evidence basis: Limited direct evidence for telmisartan in HFrEF. Valsartan (Val-HeFT) and candesartan (CHARM trials) have stronger outcome data in heart failure. Telmisartan may be considered as a class substitute under specialist supervision when preferred agents are unavailable. Used in some Indian hospital protocols as an alternative ARB for heart failure.
• Duration: Long-term
• Specialist only: Use only when ACE inhibitors and preferred ARBs (valsartan, candesartan) are not available or tolerated
• Evidence basis: Limited direct evidence for telmisartan in HFrEF. Valsartan (Val-HeFT) and candesartan (CHARM trials) have stronger outcome data in heart failure. Telmisartan may be considered as a class substitute under specialist supervision when preferred agents are unavailable. Used in some Indian hospital protocols as an alternative ARB for heart failure.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not applicable. Safety and efficacy of telmisartan have not been established in the paediatric population in India.
Secondary Indications — Paediatric doses (Off-label, if any)
Not applicable.
Clear statement: Not recommended below 18 years of age except under specialist supervision (paediatric cardiologist or nephrologist). No validated Indian paediatric dosing data exist for telmisartan. If an ARB is required in children, losartan is the preferred agent with established paediatric dosing data (IAP guidelines).
RENAL ADJUSTMENT
| Renal Status | Recommendation |
| Mild to moderate impairment (eGFR ≥30 mL/min/1.73 m²) | No dose adjustment required. Standard titration. |
| Severe impairment (eGFR <30 mL/min/1.73 m²) | Start at 20 mg once daily; titrate cautiously. Monitor renal function and potassium closely. |
| Haemodialysis | Telmisartan is not removed by haemodialysis (highly protein-bound, >99.5%). No supplemental dose required. Start at 20 mg once daily; use with caution. |
| Peritoneal dialysis | Limited data. Start at lowest dose with close monitoring. |
• Telmisartan is predominantly eliminated via biliary/faecal route (>97%); renal excretion is minimal (<1%). Therefore, accumulation in renal impairment is not a pharmacokinetic concern, but pharmacodynamic effects (hyperkalemia, worsening renal function) remain relevant.
• Monitor serum creatinine and potassium within 1–2 weeks of initiation and after each dose change. Accept up to 30% rise in creatinine from baseline; if greater, reduce dose or discontinue.
• Monitor serum creatinine and potassium within 1–2 weeks of initiation and after each dose change. Accept up to 30% rise in creatinine from baseline; if greater, reduce dose or discontinue.
HEPATIC ADJUSTMENT
• Mild impairment: No dose adjustment required.
• Moderate impairment: Maximum dose should not exceed 40 mg once daily. Telmisartan is extensively metabolised by glucuronidation in the liver and almost entirely excreted via bile. Hepatic impairment significantly increases plasma concentrations (approximately 3–4 fold increase in AUC reported in moderate impairment). Use with close monitoring of hepatic function and blood pressure.
• Severe impairment: Contraindicated. Marked increase in drug exposure and biliary excretion impairment makes use unsafe. Includes decompensated cirrhosis and cholestatic disorders.
• Biliary obstruction: Contraindicated — telmisartan elimination is almost exclusively biliary; obstruction will cause severe drug accumulation.
• Moderate impairment: Maximum dose should not exceed 40 mg once daily. Telmisartan is extensively metabolised by glucuronidation in the liver and almost entirely excreted via bile. Hepatic impairment significantly increases plasma concentrations (approximately 3–4 fold increase in AUC reported in moderate impairment). Use with close monitoring of hepatic function and blood pressure.
• Severe impairment: Contraindicated. Marked increase in drug exposure and biliary excretion impairment makes use unsafe. Includes decompensated cirrhosis and cholestatic disorders.
• Biliary obstruction: Contraindicated — telmisartan elimination is almost exclusively biliary; obstruction will cause severe drug accumulation.
CONTRAINDICATIONS
• Known hypersensitivity to telmisartan or any excipient in the formulation
• Pregnancy (second and third trimesters) — established fetotoxicity (renal dysgenesis, oligohydramnios, skull ossification defects, neonatal renal failure, and death)
• Biliary obstruction or severe cholestatic disorders — telmisartan is almost exclusively eliminated via the biliary route
• Severe hepatic impairment (Child-Pugh C)
• Concurrent use with aliskiren in patients with diabetes mellitus or renal impairment (eGFR <60 mL/min/1.73 m²) — dual RAAS blockade increases risk of hypotension, hyperkalemia, and renal failure
• Concurrent use with sacubitril/valsartan — risk of angioedema; allow 36-hour washout if switching from sacubitril/valsartan to telmisartan (though this combination is less commonly encountered than with ACE inhibitors)
• Hereditary fructose intolerance — some telmisartan formulations contain sorbitol as excipient
• Pregnancy (second and third trimesters) — established fetotoxicity (renal dysgenesis, oligohydramnios, skull ossification defects, neonatal renal failure, and death)
• Biliary obstruction or severe cholestatic disorders — telmisartan is almost exclusively eliminated via the biliary route
• Severe hepatic impairment (Child-Pugh C)
• Concurrent use with aliskiren in patients with diabetes mellitus or renal impairment (eGFR <60 mL/min/1.73 m²) — dual RAAS blockade increases risk of hypotension, hyperkalemia, and renal failure
• Concurrent use with sacubitril/valsartan — risk of angioedema; allow 36-hour washout if switching from sacubitril/valsartan to telmisartan (though this combination is less commonly encountered than with ACE inhibitors)
• Hereditary fructose intolerance — some telmisartan formulations contain sorbitol as excipient
CAUTIONS
• Volume-depleted or salt-depleted patients (e.g., on high-dose diuretics, vomiting, diarrhoea, restricted salt intake): Risk of symptomatic hypotension — correct volume status before initiation or start at lowest dose (20 mg) under observation
• Renal artery stenosis (bilateral, or unilateral in a solitary kidney): Risk of acute renal failure — monitor renal function closely if ARB is considered essential
• Pre-existing renal impairment: Pharmacodynamic risk of hyperkalemia and worsening renal function despite minimal renal drug excretion
• Aortic stenosis, mitral stenosis, or hypertrophic obstructive cardiomyopathy: Increased risk of critical hypotension
• Patients on concomitant potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes: Risk of hyperkalemia
• Primary hyperaldosteronism: ARBs are generally ineffective; specialist evaluation needed
• Major surgery or general anaesthesia: Enhanced hypotensive effect with anaesthetic agents
• Patients with ischaemic heart disease or cerebrovascular disease: Excessive blood pressure reduction may precipitate ischaemic events
• Renal artery stenosis (bilateral, or unilateral in a solitary kidney): Risk of acute renal failure — monitor renal function closely if ARB is considered essential
• Pre-existing renal impairment: Pharmacodynamic risk of hyperkalemia and worsening renal function despite minimal renal drug excretion
• Aortic stenosis, mitral stenosis, or hypertrophic obstructive cardiomyopathy: Increased risk of critical hypotension
• Patients on concomitant potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes: Risk of hyperkalemia
• Primary hyperaldosteronism: ARBs are generally ineffective; specialist evaluation needed
• Major surgery or general anaesthesia: Enhanced hypotensive effect with anaesthetic agents
• Patients with ischaemic heart disease or cerebrovascular disease: Excessive blood pressure reduction may precipitate ischaemic events
PREGNANCY
| Parameter | Detail |
| Overall safety statement | Contraindicated in second and third trimesters. Avoid in first trimester unless no suitable alternative exists. |
| Teratogenic risk | Second/third trimester exposure causes fetal renal failure, oligohydramnios, pulmonary hypoplasia, skull ossification defects, limb contractures, neonatal hypotension, and death — identical risk profile to ACE inhibitors. |
| First trimester | Limited data; epidemiological studies suggest possible risk. Discontinue as soon as pregnancy is confirmed and switch to a safe alternative. |
| Preferred alternatives | Labetalol (first-line), Methyldopa (first-line), Nifedipine extended-release (second-line) — as per Indian obstetric practice |
| Monitoring (if inadvertent exposure) | Serial ultrasound for fetal growth, amniotic fluid volume, and renal morphology; neonatal monitoring of renal function, blood pressure, and potassium after delivery |
LACTATION
| Parameter | Detail |
| Compatibility | Not recommended. Insufficient human data on excretion in breast milk. Animal studies show telmisartan is present in milk. |
| Preferred alternatives | Enalapril or captopril (ACE inhibitors with established lactation safety data); if ARB is specifically required, limited data exist for any ARB during lactation — specialist decision required |
| Expected drug levels in milk | NOT AVAILABLE in India (human lactation pharmacokinetic data not established) |
| Infant monitoring | If use is unavoidable, monitor infant for signs of hypotension (lethargy, poor feeding, excessive drowsiness), decreased urine output, and adequate weight gain |
ELDERLY
• Recommended starting dose: 20–40 mg once daily (same range as younger adults; no pharmacokinetic dose adjustment required as telmisartan clearance is not significantly age-dependent)
• Titration: May need slower dose adjustment (4-week intervals); target blood pressure goals may be less aggressive in frail elderly
• Extra risks:
• Titration: May need slower dose adjustment (4-week intervals); target blood pressure goals may be less aggressive in frail elderly
• Extra risks:
- Postural hypotension and resultant falls/fractures — particularly in patients on multiple antihypertensives or diuretics
- Age-related reduction in renal functional reserve — always check baseline eGFR and electrolytes; serum creatinine alone may underestimate renal impairment due to reduced muscle mass
- Greater susceptibility to hyperkalemia (reduced renal potassium excretion, polypharmacy)
- Assess for undiagnosed renovascular disease (atherosclerotic renal artery stenosis) before initiation, especially in patients with generalised atherosclerosis or refractory hypertension
• Monitor serum creatinine and potassium within 1–2 weeks of initiation and after each dose change
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Mechanism / Notes |
| Potassium supplements, potassium-sparing diuretics (spironolactone, amiloride, eplerenone), potassium-containing salt substitutes | Severe hyperkalemia | ARBs reduce aldosterone-mediated renal potassium excretion. If combination is essential (e.g., spironolactone in heart failure), monitor potassium within 1 week and frequently thereafter. |
| Lithium | Lithium toxicity (tremor, ataxia, confusion, renal impairment) | ARBs reduce renal lithium clearance. Monitor lithium levels closely; avoid combination if possible. |
| Aliskiren (in diabetics or CKD) | Hypotension, hyperkalemia, acute renal failure | Dual RAAS blockade. Contraindicated in patients with diabetes or eGFR <60 mL/min/1.73 m². |
| ACE inhibitors (dual RAAS blockade) | No additional cardiovascular benefit; increased renal adverse events, hyperkalemia, and hypotension | ONTARGET combination arm demonstrated harm from dual blockade. Do not combine telmisartan with any ACE inhibitor. |
| NSAIDs (including COX-2 inhibitors) — chronic use | Reduced antihypertensive effect; increased risk of acute kidney injury and hyperkalemia | NSAIDs reduce renal prostaglandin synthesis → decreased renal blood flow. The ”triple whammy“ combination (ARB + diuretic + NSAID) markedly increases AKI risk. Short-term NSAID use may be acceptable with monitoring. |
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Notes |
| Diuretics (thiazides, loop diuretics) | Enhanced first-dose hypotension | Reduce or hold diuretic 2–3 days before telmisartan initiation, or start telmisartan at 20 mg under observation. Once stable, combination is therapeutically beneficial and widely used in FDCs. |
| Digoxin | Median increase of approximately 20% in digoxin plasma concentrations | Mechanism not fully elucidated. Monitor serum digoxin levels when initiating or adjusting telmisartan dose; particularly relevant in patients with renal impairment. |
| Antidiabetic agents (insulin, sulfonylureas, metformin) | Enhanced hypoglycaemic effect | ARBs may improve insulin sensitivity. Monitor blood glucose more frequently when initiating or titrating telmisartan in diabetic patients. |
| Cotrimoxazole (trimethoprim-sulfamethoxazole) | Hyperkalemia | Trimethoprim has potassium-sparing diuretic-like activity. Monitor potassium, especially in elderly and those with renal impairment. |
| Corticosteroids, sympathomimetics | Diminished antihypertensive effect | Sodium and water retention by corticosteroids; sympathomimetics oppose vasodilatory action. |
| Ramipril/other ACE inhibitors (for switching, not combination) | Not an interaction per se, but note: no washout period required when switching from ACE inhibitor to telmisartan | Simply substitute at the next scheduled dose. However, if switching from sacubitril/valsartan, a 36-hour washout is mandatory before starting any ACE inhibitor (not before telmisartan, as ARB component is already present). |
| Warfarin | No clinically significant pharmacokinetic interaction reported | No dose adjustment required, but as with all antihypertensives, monitor for any change in INR when adding or stopping telmisartan. |
COMMON ADVERSE EFFECTS
• Dizziness and light-headedness — related to blood pressure reduction, more common early in treatment
• Upper respiratory tract infections (nasopharyngitis, sinusitis)
• Back pain and myalgia
• Diarrhoea
• Fatigue
• Hypotension — particularly in volume-depleted patients
• Upper respiratory tract infections (nasopharyngitis, sinusitis)
• Back pain and myalgia
• Diarrhoea
• Fatigue
• Hypotension — particularly in volume-depleted patients
• Notably absent: dry cough. Unlike ACE inhibitors, ARBs do not inhibit bradykinin degradation and therefore carry a negligible risk of cough. This is the principal reason for switching from ACE inhibitors to ARBs in clinical practice.
SERIOUS ADVERSE EFFECTS
• Angioedema: Rare with ARBs but reported. Requires immediate discontinuation and emergency management. Risk is lower than with ACE inhibitors but not zero. Exercise caution in patients with a history of ACE inhibitor-induced angioedema — approximately 2–17% cross-reactivity risk. Do not re-challenge if angioedema occurs with telmisartan.
• Hyperkalemia: Especially in renal impairment, diabetes, or concurrent potassium-elevating agents. Can cause life-threatening cardiac arrhythmias.
• Acute renal failure: Particularly in bilateral renal artery stenosis, severe heart failure, or volume depletion.
• Severe hypotension: May cause syncope, stroke, or myocardial ischaemia in susceptible patients.
• Hepatotoxicity: Rare; cases of hepatocellular injury have been reported. Discontinue if marked elevation of hepatic enzymes or jaundice develops.
• Rhabdomyolysis: Very rare; reported in post-marketing surveillance. Monitor for unexplained muscle pain, tenderness, or weakness with elevated creatine kinase levels.
• Hyperkalemia: Especially in renal impairment, diabetes, or concurrent potassium-elevating agents. Can cause life-threatening cardiac arrhythmias.
• Acute renal failure: Particularly in bilateral renal artery stenosis, severe heart failure, or volume depletion.
• Severe hypotension: May cause syncope, stroke, or myocardial ischaemia in susceptible patients.
• Hepatotoxicity: Rare; cases of hepatocellular injury have been reported. Discontinue if marked elevation of hepatic enzymes or jaundice develops.
• Rhabdomyolysis: Very rare; reported in post-marketing surveillance. Monitor for unexplained muscle pain, tenderness, or weakness with elevated creatine kinase levels.
MONITORING REQUIREMENTS
| Timing | Parameters |
| Baseline (before initiation) | Blood pressure; serum creatinine and eGFR; serum potassium and sodium; hepatic function (especially if hepatic impairment suspected); urinalysis (proteinuria if diabetic nephropathy indication) |
| 1–2 weeks after initiation or each dose change | Blood pressure; serum creatinine and potassium. Accept up to 30% rise in creatinine from baseline. If rise exceeds 30% or potassium >5.5 mmol/L, reduce dose or discontinue. |
| Monthly for first 3 months | Blood pressure; renal function; potassium |
| Long-term (stable patients) | Blood pressure, serum creatinine, and potassium every 3–6 months; hepatic function periodically if baseline impairment |
| If used for proteinuric CKD | Urine protein/creatinine ratio or spot albumin/creatinine ratio at baseline and every 3–6 months to assess antiproteinuric response |
BRANDS AVAILABLE IN INDIA
• Telma (Glenmark) — most widely prescribed brand in India
• Cresar (Cipla)
• Telmikind (Mankind)
• Telsar (Unichem)
• Telvas (Aristo)
• Cresar (Cipla)
• Telmikind (Mankind)
• Telsar (Unichem)
• Telvas (Aristo)
FDCs widely available in India:
• Telmisartan + Hydrochlorothiazide (e.g., Telma-H, Cresar-H): 40/12.5 mg, 80/12.5 mg
• Telmisartan + Amlodipine (e.g., Telma-AM, Cresar Plus): 40/5 mg, 80/5 mg
• Telmisartan + Chlorthalidone (e.g., Telma-CT): 40/12.5 mg, 80/12.5 mg
• Telmisartan + Hydrochlorothiazide (e.g., Telma-H, Cresar-H): 40/12.5 mg, 80/12.5 mg
• Telmisartan + Amlodipine (e.g., Telma-AM, Cresar Plus): 40/5 mg, 80/5 mg
• Telmisartan + Chlorthalidone (e.g., Telma-CT): 40/12.5 mg, 80/12.5 mg
PRICE RANGE (INR)
• 20 mg tablet: ₹3–₹8 per tablet
• 40 mg tablet: ₹4–₹12 per tablet
• 80 mg tablet: ₹8–₹20 per tablet
• Telmisartan 40 mg is listed on NLEM India 2022 and is under NPPA price control — ceiling price applies to 40 mg tablets
• Government facility supply: Widely available through government procurement; telmisartan is one of the most commonly stocked ARBs in public health facilities in India
• 40 mg tablet: ₹4–₹12 per tablet
• 80 mg tablet: ₹8–₹20 per tablet
• Telmisartan 40 mg is listed on NLEM India 2022 and is under NPPA price control — ceiling price applies to 40 mg tablets
• Government facility supply: Widely available through government procurement; telmisartan is one of the most commonly stocked ARBs in public health facilities in India
CLINICAL PEARLS
• Longest-acting ARB — true once-daily dosing: Telmisartan has a half-life of ~24 hours (longest among all ARBs), providing consistent 24-hour blood pressure control. It offers superior trough-to-peak ratio, making it particularly useful in patients with poor adherence to twice-daily regimens or those with early-morning blood pressure surge.
• ACE inhibitor cough — switch to telmisartan: The most common clinical scenario for initiating telmisartan in India is switching from an ACE inhibitor (enalapril, ramipril) due to persistent dry cough. No washout period is required — simply substitute at the next scheduled dose. ARBs do not cause cough because they do not affect bradykinin metabolism.
• Hepatic metabolism — unique among RAAS blockers: Unlike most other ARBs and ACE inhibitors, telmisartan is almost exclusively eliminated via biliary excretion (>97%). This means renal impairment has minimal impact on drug clearance, but hepatic impairment significantly increases drug exposure. Contraindicated in biliary obstruction and severe liver disease — a distinction from other ARBs.
• NLEM India listing and cost advantage: Telmisartan 40 mg is on the NLEM 2022, making it price-controlled and widely available. It is the preferred ARB in Indian public health programmes for hypertension management.
• Not a direct substitute in heart failure: For HFrEF, valsartan and candesartan have the strongest evidence among ARBs (Val-HeFT, CHARM trials). Telmisartan should be used for heart failure only when these preferred agents and ACE inhibitors are unavailable or not tolerated.
• PPAR-γ partial agonist activity: Telmisartan has unique partial PPAR-γ agonist properties, providing modest insulin-sensitising and metabolic benefits. This makes it a rational choice in hypertensive patients with metabolic syndrome or type 2 diabetes, though the clinical magnitude of this effect is modest compared to dedicated antidiabetic agents.
• ACE inhibitor cough — switch to telmisartan: The most common clinical scenario for initiating telmisartan in India is switching from an ACE inhibitor (enalapril, ramipril) due to persistent dry cough. No washout period is required — simply substitute at the next scheduled dose. ARBs do not cause cough because they do not affect bradykinin metabolism.
• Hepatic metabolism — unique among RAAS blockers: Unlike most other ARBs and ACE inhibitors, telmisartan is almost exclusively eliminated via biliary excretion (>97%). This means renal impairment has minimal impact on drug clearance, but hepatic impairment significantly increases drug exposure. Contraindicated in biliary obstruction and severe liver disease — a distinction from other ARBs.
• NLEM India listing and cost advantage: Telmisartan 40 mg is on the NLEM 2022, making it price-controlled and widely available. It is the preferred ARB in Indian public health programmes for hypertension management.
• Not a direct substitute in heart failure: For HFrEF, valsartan and candesartan have the strongest evidence among ARBs (Val-HeFT, CHARM trials). Telmisartan should be used for heart failure only when these preferred agents and ACE inhibitors are unavailable or not tolerated.
• PPAR-γ partial agonist activity: Telmisartan has unique partial PPAR-γ agonist properties, providing modest insulin-sensitising and metabolic benefits. This makes it a rational choice in hypertensive patients with metabolic syndrome or type 2 diabetes, though the clinical magnitude of this effect is modest compared to dedicated antidiabetic agents.
VERSION
RxIndia v0.1 — 01 Mar 2026
REFERENCES
• CDSCO product inserts (Telmisartan)
• Indian Pharmacopoeia
• NLEM India 2022 (telmisartan 40 mg listed)
• API Textbook of Medicine
• AIIMS Treatment Guidelines
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• ICMR Guidelines (hypertension management)
• ONTARGET Investigators. N Engl J Med 2008;358:1547–59 (cardiovascular risk reduction — primary evidence)
• TRANSCEND Investigators. Lancet 2008;372:1174–83 (ACE inhibitor-intolerant patients — supportive evidence)
• Barnett AH et al. (DETAIL trial) N Engl J Med 2004;351:1952–61 (telmisartan vs enalapril in diabetic nephropathy — off-label evidence basis)
• Indian Pharmacopoeia
• NLEM India 2022 (telmisartan 40 mg listed)
• API Textbook of Medicine
• AIIMS Treatment Guidelines
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• ICMR Guidelines (hypertension management)
• ONTARGET Investigators. N Engl J Med 2008;358:1547–59 (cardiovascular risk reduction — primary evidence)
• TRANSCEND Investigators. Lancet 2008;372:1174–83 (ACE inhibitor-intolerant patients — supportive evidence)
• Barnett AH et al. (DETAIL trial) N Engl J Med 2004;351:1952–61 (telmisartan vs enalapril in diabetic nephropathy — off-label evidence basis)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.